{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:18:57Z","timestamp":1791620337373,"version":"4.3.4"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0188482","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T13:31:14Z","timestamp":1511184674000},"page":"e0188482","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":67,"title":["The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-1490","authenticated-orcid":true,"given":"Anne Sig","family":"Vestergaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Skj\u00f8th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben Bjerregaard","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Holger","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"key":"ref1","first-page":"1","article-title":"Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care","volume":"6","author":"DA Lane","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"P Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"ref3","unstructured":"The Danish Counsil for the Use of Expensive Hospital Medicines [R\u00e5det for Anvendelse af Dyr Sygehusmedicin]. Background memorandum for oral anticoagulant therapy in non-valvular atrial fibrillation [Baggrundsnotat for oral antikoagulationsbehandling ved non-valvul\u00e6r atrieflimren] 2016:1\u20138. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.regioner.dk\/media\/3415\/beh-atrieflimmer-juni-2016.pdf\" xlink:type=\"simple\">http:\/\/www.regioner.dk\/media\/3415\/beh-atrieflimmer-juni-2016.pdf<\/ext-link> (accessed January 13, 2017)."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1378\/chest.126.6.1938","article-title":"Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation\u2014A Systematic Review and Metaanalysis","volume":"126","author":"MW Reynolds","year":"2004","journal-title":"CHEST"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Y Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"SJ Connolly","year":"2008","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/jth.12041","article-title":"The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation","volume":"11","author":"HA Van Den Ham","year":"2013","journal-title":"J Thromb Haemost"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1161\/STROKEAHA.115.010614","article-title":"Relationship of Age with Stroke and Death in Anticoagulated Patients with Nonvalvular Atrial Fibrillation: AMADEUS Trial","volume":"46","author":"K Senoo","year":"2015","journal-title":"Stroke"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1477-9560-12-14","article-title":"Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression","volume":"12","author":"ES Mearns","year":"2014","journal-title":"Thromb J"},{"key":"ref10","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and elaboration","volume":"151","author":"A Liberati","year":"2009","journal-title":"Ann Intern Med Acad Clin"},{"key":"ref11","first-page":"974","article-title":"J Epidemiol Community Health","volume":"67","author":"JJ Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","article-title":"Introduction to Meta-analysis","author":"M Borenstein","year":"2009"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"SG Thompson","year":"2002","journal-title":"Stat Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial","volume":"376","author":"L Wallentin","year":"2010","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","article-title":"Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation","volume":"127","author":"L Wallentin","year":"2013","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e000521","DOI":"10.1161\/JAHA.113.000521","article-title":"Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial","volume":"3","author":"JP Piccini","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"S Connolly","year":"2006","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/eurheartj\/ehu083","article-title":"Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: Results from the ROCKET AF trial","volume":"35","author":"JP Piccini","year":"2014","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjopharm.2008.03.005","article-title":"Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice","volume":"6","author":"AH Abdelhafiz","year":"2008","journal-title":"Am J Geriatr Pharmacother"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial","volume":"371","author":"HR B\u00fcller","year":"2008","journal-title":"Lancet"},{"key":"ref25","first-page":"697","article-title":"The safety and adequacy of antithrombotic therapy for atrial fibrillation: A regional cohort study","volume":"56","author":"C Burton","year":"2006","journal-title":"Br J Gen Pract"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/eurheartj\/eht039","article-title":"Betrixaban compared with warfarin in patients with atrial fibrillation: Results of a phase 2, randomized, dose-ranging study (Explore-Xa)","volume":"34","author":"SJ Connolly","year":"2013","journal-title":"Eur Heart J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1185\/030079905X75050","article-title":"Anticoagulation in patients with non-valvular atrial fibrillation: An evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population","volume":"21","author":"CJ Currie","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"EM Hylek","year":"2007","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.amjopharm.2009.06.002","article-title":"Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and\/or early-stage dementia: A single-center, retrospective, observational study","volume":"7","author":"LG Jacobs","year":"2009","journal-title":"Am J Geriatr Pharmacother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/jth.13025","article-title":"A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: The oral factor Xa inhibitor for prophylaxis of stroke in atrial","volume":"13","author":"GYH Lip","year":"2015","journal-title":"J Thromb Haemost"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"J Mant","year":"2007","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1345\/aph.1E169","article-title":"Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study","volume":"39","author":"J Menzin","year":"2005","journal-title":"Ann Pharmacother"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1345\/aph.1K157","article-title":"Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: Comparison of anticoagulation clinic versus usual care","volume":"42","author":"MB Nichol","year":"2008","journal-title":"Ann Pharmacother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2005.01605.x","article-title":"Gains and losses of warfarin therapy as performed in an anticoagulation clinic","volume":"259","author":"AM Njaastad","year":"2006","journal-title":"J Intern Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ijcard.2015.08.054","article-title":"Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation","volume":"201","author":"D Pastori","year":"2015","journal-title":"Int J Cardiol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1160\/TH09-05-0311","article-title":"Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation: A randomised primary prevention trial","volume":"103","author":"V Pengo","year":"2010","journal-title":"Thromb Haemost"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.thromres.2007.05.014","article-title":"Risk of bleeding in very old atrial fibrillation patients on warfarin: Relationship with ageing and CHADS2 score","volume":"121","author":"D Poli","year":"2007","journal-title":"Thromb Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2009.05.046","article-title":"Bleeding Risk During Oral Anticoagulation in Atrial Fibrillation Patients Older Than 80 Years","volume":"54","author":"D Poli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijcard.2007.10.041","article-title":"The quality of anticoagulation on functional outcome and mortality for TIA\/stroke in atrial fibrillation patients","volume":"132","author":"D Poli","year":"2009","journal-title":"Int J Cardiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1378\/chest.10-3024","article-title":"Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation","volume":"140","author":"D Poli","year":"2011","journal-title":"Chest"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation: A Randomized Controlled Trial","volume":"312","author":"VY Reddy","year":"2014","journal-title":"Jama"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1538-7836.2008.03075.x","article-title":"Warfarin for atrial fibrillation in community-based practise","volume":"6","author":"AJ Rose","year":"2008","journal-title":"J Thromb Haemost"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.thromres.2015.10.031","article-title":"Warfarin treatment complications do not correlate to cTTR when above 70%","volume":"136","author":"P Sand\u00e9n","year":"2015","journal-title":"Thromb Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"DE Singer","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.amjcard.2012.08.014","article-title":"Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM)","volume":"110","author":"RM Sullivan","year":"2012","journal-title":"Am J Cardiol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MBC.0b013e32831be9da","article-title":"Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation","volume":"20","author":"E Tincani","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5603\/CJ.a2015.0035","article-title":"Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in turkey: Perspectives from the observational, prospective WATER registry","volume":"22","author":"UO Turk","year":"2015","journal-title":"Cardiol J"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control results from SPORTIF III and V","volume":"167","author":"HD White","year":"2007","journal-title":"Arch Intern Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point the decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"MH Eckman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/jech.2003.008466","article-title":"Bias","volume":"58","author":"M Delgado-Rodr\u00edguez","year":"2004","journal-title":"J Epidemiol Community Health"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.thromres.2014.01.013","article-title":"Comparing patient-level and site-level anticoagulation control as predictors of adverse events","volume":"133","author":"RS Cancino","year":"2014","journal-title":"Thromb Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1247.e23","DOI":"10.1016\/j.cjca.2015.10.029","article-title":"Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation","volume":"32","author":"PH Chan","year":"2016","journal-title":"Can J Cardiol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.thromres.2011.07.004","article-title":"Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation","volume":"129","author":"M Lind","year":"2012","journal-title":"Thromb Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0188482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T19:13:03Z","timestamp":1540235583000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0188482"}},"subtitle":[],"editor":[{"given":"Michael","family":"Nagler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0188482","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,20]]}}}